Tech Company Financing Transactions
Sironax Funding Round
On 8/2/2022, Sironax raised $200 million in Series B funding from Gaorong Capital, Yunfeng Capital and Abu Dhabi Investment Authority.
Transaction Overview
Company Name
Announced On
8/2/2022
Transaction Type
Venture Equity
Amount
$200,000,000
Round
Series B
Investors
Proceeds Purpose
Sironax plans to use the proceeds to support the ongoing clinical development of its portfolio of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors in addition to the continued expansion of its R&D footprint and pipeline of potential best- and first-in-class candidates for age-related degenerative diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Fl 8-10, Building 2, Medical Technology Center Phase II Zhon
Beijing, 102206
CN
Beijing, 102206
CN
Phone
Undisclosed
Website
Email Address
Overview
Sironax is a pharmaceuticals company for inflammatory and neurodegenerative diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gang Ren
Co-Founder
Xiaodong Wang
Founder
Zhiyuan Zhang
Browse more venture capital transactions:
Prev: 8/2/2022: Eleven Therapeutics venture capital transaction
Next: 8/2/2022: Bemlo venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs